Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University and Capital Medical University, Beijing Tongren Hospital, Beijing 100730, China.
Cancer Biol Med. 2020 Aug 15;17(3):726-739. doi: 10.20892/j.issn.2095-3941.2020.0073.
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with high heterogeneity and a high recurrence rate. How heterogenous cell populations contribute to relapse remains to be elucidated. We performed single cell RNA sequencing (scRNA-seq) on approximately 4,000 bone marrow cells sampled from one patient with multidrug resistant MCL. We identified 10 subpopulations comprising 4 malignant B cell subtypes, 3 T cell subtypes, 2 dendritic cell subtypes and 1 natural killer (NK) cell subtype. Subsequently, we identified cell markers, including a series of genes associated with immune escape and drug resistance. In addition, we explored the roles of these genes in the mechanism of immune escape and drug resistance, and we verified the expression imbalance and clinical prognostic potential by using GEO datasets including 211 MCL samples. The major immune escape mechanisms of MCL included anti-perforin activity, decreased immunogenicity and direct inhibition of apoptosis and cell killing, as mediated by type I and II B cells. The drug resistance mechanisms of different cell clusters included drug metabolism, DNA damage repair, apoptosis and survival promotion. Type III B cells closely communicate with other cells. The key genes involved in the resistance mechanisms showed dysregulated expression and may have significant clinical prognostic value. This study investigated potential immune escape and drug resistance mechanisms in MCL. The results may guide individualized treatment and promote the development of therapeutic drugs.
套细胞淋巴瘤(Mantle cell lymphoma,MCL)是一种罕见的非霍奇金淋巴瘤(Non-Hodgkin lymphoma,NHL)亚型,具有高度异质性和高复发率。异质性细胞群体如何促进复发仍有待阐明。我们对一名多药耐药 MCL 患者的约 4000 个骨髓细胞进行了单细胞 RNA 测序(single cell RNA sequencing,scRNA-seq)。我们鉴定了 10 个亚群,包括 4 种恶性 B 细胞亚型、3 种 T 细胞亚型、2 种树突状细胞亚型和 1 种自然杀伤(Natural killer,NK)细胞亚型。随后,我们鉴定了细胞标志物,包括一系列与免疫逃逸和耐药相关的基因。此外,我们通过使用包括 211 个 MCL 样本的 GEO 数据集,探索了这些基因在免疫逃逸和耐药机制中的作用,并验证了表达失衡和临床预后潜力。MCL 的主要免疫逃逸机制包括抗穿孔素活性、降低免疫原性和直接抑制凋亡和细胞杀伤,这是由 I 型和 II 型 B 细胞介导的。不同细胞簇的耐药机制包括药物代谢、DNA 损伤修复、凋亡和生存促进。III 型 B 细胞与其他细胞密切通讯。参与耐药机制的关键基因表达失调,可能具有重要的临床预后价值。本研究探讨了 MCL 中潜在的免疫逃逸和耐药机制。研究结果可能指导个体化治疗并促进治疗药物的发展。